Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from LUMINOUS, a Global Real-World Study.
TypeMulticentre Study; Observational Study; Peer-Reviewed Publication; Prospective Study
KeywordAnti-VEGF therapy; LUMINOUS; Effectiveness; Neovascular age-related macular degeneration; Ranibizumab; Real-world; Treatment-naive; Visual acuity; Treatment patterns; Anti–vascular endothelial growth factor; Angiogenesis inhibitors; Choroidal neovascularization; Intravitreal injections; Treatment outcomes; Vascular endothelial growth factor A; Wet macular degeneration; VEGFA protein
MetadataShow full item record
AbstractPurpose: To evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg in treatment-naive patients with neovascular age-related macular degeneration enrolled in LUMINOUS study. Methods: This 5-year, prospective, multicenter, observational study recruited 30,138 adult patients (treatment-naive or previously treated with ranibizumab or other ocular treatments) who were treated according to the local ranibizumab label. Results: Six thousand two hundred and forty-one treatment-naive neovascular age-related macular degeneration patients were recruited. Baseline (BL) demographics were, mean (SD) age 75.0 (10.2) years, 54.9% females, and 66.5% Caucasian. The mean (SD) visual acuity (VA; letters) gain at 1 year was 3.1 (16.51) (n = 3,379; BLVA, 51.9 letters [Snellen: 20/92]) with a mean (SD) of 5.0 (2.7) injections and 8.8 (3.3) monitoring visits. Presented by injection frequencies <3 (n = 537), 3 to 6 (n = 1,924), and >6 (n = 918), visual acuity gains were 1.6 (14.93), 3.3 (16.57), and 3.7 (17.21) letters, respectively. Stratified by BLVA <23 (n = 382), 23 to <39 (n = 559), 39 to <60 (n = 929), 60 to <74 (n = 994), and ≥74 (n = 515), visual acuity change was 12.6 (20.63), 6.7 (17.88), 3.6 (16.41), 0.3 (13.83), and -3.0 (11.82) letters, respectively. The incidence of ocular/nonocular adverse events was 8.2%/12.8% and serious adverse events were 0.9%/7.4%, respectively. Conclusion: These results demonstrate the effectiveness and safety of ranibizumab in treatment-naive neovascular age-related macular degeneration patients.
CitationHolz FG, Figueroa MS, Bandello F, Yang Y, Ohji M, Dai H, Wykrota H, Sharma S, Dunger-Baldauf C, Lacey S, Macfadden W, Mitchell P; all the LUMINOUS study investigators. RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study. Retina. 2020 Sep;40(9):1673-1685. doi: 10.1097/IAE.0000000000002670. PMID: 31764612; PMCID: PMC7447127.
Publisher Linkhttps://journals.lww.com/retinajournal/Fulltext/2020/09000/RANIBIZUMAB_TREATMENT_IN_TREATMENT_NAIVE.5.aspx; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447127/
RightsAttribution 3.0 United States
The following license files are associated with this item:
Showing items related by title, author, creator and subject.
The B-MaP-C study: Breast cancer management pathways during the COVID-19 pandemic: study protocol. Vidya, Raghavan (International Journal of Surgery Protocols, Elsevier, 2020-07-29)Introduction: Approximately 55000 women in the United Kingdom are diagnosed with new breast cancer annually. Since emerging in December 2019, SARS-CoV-2 (coronavirus disease 2019, COVID-19) has become a global pandemic, ...
Absence of monitoring in withdrawal of clinically-assisted nutrition and hydration (CANH) and other treatments: a cause for concern? Gray, Alice (Clinical Medicine Journal, Royal College of Physicians, 2021-05-17)Since 2018, there has been no requirement to bring decisions about the withdrawal of clinically-assisted nutrition and hydration (CANH) in patients with persistent disorders of consciousness before the courts, providing ...
Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals. Rylance, Paul (Journal of Hypertension, Lippincott, Williams & Wilkins, 2020-06-01)Objective: Nonadherence to medication is present in at least 50% of patients with apparent treatment-resistant hypertension. We examined the factors associated with nonadherence as detected by a liquid chromatography-tandem ...